Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Thursday.
Several other research analysts also recently commented on TEVA. Barclays lifted their price target on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Jefferies Financial Group upped their target price on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Wednesday, July 10th. Finally, UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $18.89.
Check Out Our Latest Research Report on TEVA
Teva Pharmaceutical Industries Stock Performance
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.03. The company had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. On average, research analysts expect that Teva Pharmaceutical Industries will post 2.33 EPS for the current year.
Insider Activity
In other news, insider Eric A. Hughes sold 24,537 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the sale, the insider now directly owns 45,060 shares in the company, valued at approximately $777,285. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.55% of the stock is owned by company insiders.
Institutional Investors Weigh In On Teva Pharmaceutical Industries
Several institutional investors and hedge funds have recently made changes to their positions in the company. New Covenant Trust Company N.A. bought a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $28,000. EntryPoint Capital LLC bought a new position in Teva Pharmaceutical Industries in the 1st quarter valued at $30,000. UMB Bank n.a. boosted its stake in Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after purchasing an additional 2,067 shares in the last quarter. Beach Investment Counsel Inc. PA bought a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth $48,000. Finally, Byrne Asset Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at $52,000. Institutional investors and hedge funds own 54.05% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Read More
- Five stocks we like better than Teva Pharmaceutical Industries
- ESG Stocks, What Investors Should Know
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- What is Short Interest? How to Use It
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.